Image Analysis Tools for mpMRI Prostate Cancer Diagnosis Using PI-RADS

Information

  • Research Project
  • 9559275
  • ApplicationId
    9559275
  • Core Project Number
    R41CA224888
  • Full Project Number
    1R41CA224888-01A1
  • Serial Number
    224888
  • FOA Number
    PA-17-303
  • Sub Project Id
  • Project Start Date
    5/1/2018 - 6 years ago
  • Project End Date
    4/30/2019 - 5 years ago
  • Program Officer Name
    ZHAO, MING
  • Budget Start Date
    5/1/2018 - 6 years ago
  • Budget End Date
    4/30/2019 - 5 years ago
  • Fiscal Year
    2018
  • Support Year
    01
  • Suffix
    A1
  • Award Notice Date
    4/27/2018 - 6 years ago

Image Analysis Tools for mpMRI Prostate Cancer Diagnosis Using PI-RADS

ABSTRACT Prostate cancer (PCa) is one of the most commonly occurring forms of cancer, accounting for 21% of all cancer in men. Multi-parametric magnetic resonance imaging (mpMRI) has led to improved capabilities for detecting, localizing, and staging PCa. Combined with image-guided prostate biopsy, mpMRI has helped to improve diagnosis of clinically significant PCa, which helps to reduce mortality as well as unnecessary biopsies or treatments. Until recently, the diagnostic capabilities of mpMRI were limited by lack of standardization in imaging, interpretation, and reporting methods, which are all subject to high inter- and intra-observer variability. To address these problems, the Prostate Imaging-Reporting and Data System (PI-RADS) was designed to standardize the reporting of PCa. PI-RADS aims to standardize imaging acquisition parameters for mpMRI, simplify radiological reporting, and develop assessment categories to stratify levels of PCa. A recent meta- analysis reported the diagnostic performance of PI-RADS to have a high pooled sensitivity of 89% and specificity of 73%; unfortunately, there is still high variability in these results. The current clinical practice for interpreting mpMRI has limitations that may contribute to this variation. Currently, no image registration exists between the images, and radiologists rely on mental alignment of the images while reading a set of mpMR images, which introduces a potential source of variability into PCa diagnosis. Localization and reporting of PCa is specified with respect to the PI-RADS sector atlas, and this is another source of operator variation. An explicit manual delineation of the prostate into its constituent PI-RADS sectors would reduce variation, but this is time-consuming and infeasible in the clinical setting. The overarching goal of this proposal is to reduce the inter- and intra-observer variability while interpreting mpMRI images using the PI-RADS protocol to improve consistency and accuracy of PCa diagnosis. The primary innovation is creation of a population of PI-RADS sector atlases and their application to automatically segment anatomical prostate images with respect to this atlas label protocol. This project is significant in that it has the potential to reduce the variability in PCa interpretation and reporting by providing automated image analysis tools. While radiological results are currently communicated in a non-standardized format, the proposed work will facilitate development of automated electronic report generation capabilities to foster data sharing and collaborations. Ultimately, enhancements from this project will create a novel feature for Eigen?s (the applicant company?s) FDA 510(k)- cleared imaging product, ProFuse, that should improve the diagnosis of PCa. In Aim 1 of this project, a tool to co-register and visualize multi-parametric prostate MR imaging will be developed. In Aim 2, an image segmentation method to automatically localize the anatomical PI-RADS sector map standard within the prostate will be developed. Both aims will utilize a database of existing mpMRI images to develop and validate the algorithms and validate their accuracy.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R41
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    265877
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    394
  • Ed Inst. Type
  • Funding ICs
    NCI:265877\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ZMK MEDICAL TECHNOLOGIES, D/B/A EIGEN
  • Organization Department
  • Organization DUNS
    963346627
  • Organization City
    GRASS VALLEY
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    959459549
  • Organization District
    UNITED STATES